Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Morita S, Nakata B, Tsuji A, Mitachi Y, Shirasaka T, Saji S, Ohashi Y, Sakamoto J, Hirakawa K. Morita S, et al. Among authors: saji s. Jpn J Clin Oncol. 2007 Dec;37(12):924-9. doi: 10.1093/jjco/hym124. Jpn J Clin Oncol. 2007. PMID: 18211983 Clinical Trial.
Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Tanaka H, Kanda M, Morita S, Taguri M, Nishikawa K, Shimada M, Muguruma K, Koeda K, Takahashi M, Nakamori M, Konno H, Tsuji A, Hosoya Y, Shirasaka T, Yamamitsu S, Sowa M, Kitajima M, Okajima M, Kobayashi M, Sakamoto J, Saji S, Hirakawa K. Tanaka H, et al. Among authors: saji s. Int J Clin Oncol. 2017 Dec;22(6):1052-1059. doi: 10.1007/s10147-017-1157-3. Epub 2017 Jun 30. Int J Clin Oncol. 2017. PMID: 28667408 Free PMC article. Clinical Trial.
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
Morita S, Ohashi Y, Hirakawa K, Nakata B, Saji S, Sakamoto J. Morita S, et al. Among authors: saji s. Jpn J Clin Oncol. 2004 Mar;34(3):159-61. doi: 10.1093/jjco/hyh031. Jpn J Clin Oncol. 2004. PMID: 15078913 Clinical Trial.
Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).
Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M. Yoshino S, et al. Among authors: saji s. Eur J Cancer. 2016 Sep;65:164-71. doi: 10.1016/j.ejca.2016.06.012. Epub 2016 Aug 5. Eur J Cancer. 2016. PMID: 27501505 Free article. Clinical Trial.
Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K, Ishida H, Nishimura G, Sasaki K, Morita T, Hazama S, Maeda K, Mishima H, Ike H, Sadahiro S, Sugihara K, Okajima M, Saji S, Sakamoto J, Tomita N. Suto T, et al. Among authors: saji s. Int J Clin Oncol. 2017 Jun;22(3):494-504. doi: 10.1007/s10147-016-1083-9. Epub 2017 Jan 11. Int J Clin Oncol. 2017. PMID: 28078540 Free PMC article. Clinical Trial.
Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001).
Shimada M, Morine Y, Nagano H, Hatano E, Kaiho T, Miyazaki M, Kono T, Kamiyama T, Morita S, Sakamoto J, Kusano M, Saji S, Kanematsu T, Kitajima M. Shimada M, et al. Among authors: saji s. Int J Clin Oncol. 2015 Feb;20(1):95-104. doi: 10.1007/s10147-014-0678-2. Epub 2014 Mar 6. Int J Clin Oncol. 2015. PMID: 24595550 Clinical Trial.
591 results